Oruka Therapeutics' (ORKA) "Outperform" Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) in a research report report published on Monday,RTT News reports. The brokerage currently has a $40.00 price objective on the stock.

ORKA has been the topic of a number of other research reports. BTIG Research assumed coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They set a "buy" rating on the stock. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded down $0.31 during midday trading on Monday, reaching $14.23. 69,615 shares of the stock were exchanged, compared to its average volume of 365,089. The company's fifty day moving average is $12.43 and its 200-day moving average is $11.52. The firm has a market cap of $532.77 million, a PE ratio of -3.15 and a beta of -0.34. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $52.32.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. On average, sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in ORKA. Vanguard Group Inc. boosted its stake in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after purchasing an additional 1,047,245 shares in the last quarter. FMR LLC boosted its position in Oruka Therapeutics by 17.7% during the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after buying an additional 830,000 shares during the period. Braidwell LP boosted its position in Oruka Therapeutics by 122.5% during the 4th quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after buying an additional 631,950 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Oruka Therapeutics by 259.7% during the 4th quarter. Janus Henderson Group PLC now owns 849,410 shares of the company's stock valued at $16,415,000 after buying an additional 613,294 shares during the period. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.